Press releases | Deinove

16.04.2018

DEINOVE and GREENTECH announce the launch of HEBELYS®, the first cosmetic active ingredient resulting from their collaboration

HEBELYS ® is a natural active ingredient produced by the fermentation of Sphingomonas , a bacterium belonging to the DEINOVE proprietary...

13.04.2018

MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...

10.04.2018

Deinove scientific platform has designed an exclusive Deinococcus fermentation process to deliver the first pure Phytoene for application...

29.03.2018

Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...

22.03.2018

The program developed by REDX PHARMA focuses on a new class of antibiotics aimed at treating the most lethal infections (caused by...

08.03.2018

DEINOVE expands the AGIR project’s field of investigation for the discovery of novel antibiotic structures by accessing the strain bank of...

26.02.2018

World premiere in Deinococcus fermentation successfully performed at the several cubic meters scale; The first batch of carotenoid...

19.02.2018

DEINOVE (Euronext Growth Paris: ALDEI), a biotech company that discovers, develops, and produces high-value compounds from rare bacteria,...

30.01.2018

Development of an innovative cosmetic active ingredient combining the exclusive properties of Deinove’s strains and Oléos' patented Oleo-...

18.12.2017

Deinove’s production process gaining momentum: fermentation scale-up is planned at the BIOGIS Center, SAS PIVERT's technological platform...